Mirae Asset Global Investments Co. Ltd. Acquires New Position in Halozyme Therapeutics, Inc. $HALO

Mirae Asset Global Investments Co. Ltd. acquired a new stake in Halozyme Therapeutics, Inc. (NASDAQ:HALO) during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 5,800 shares of the biopharmaceutical company’s stock, valued at approximately $640,000.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in HALO. Horizon Investment Services LLC acquired a new stake in Halozyme Therapeutics during the 2nd quarter worth about $2,254,000. WINTON GROUP Ltd raised its stake in shares of Halozyme Therapeutics by 704.6% during the 2nd quarter. WINTON GROUP Ltd now owns 60,348 shares of the biopharmaceutical company’s stock valued at $4,723,000 after buying an additional 52,848 shares during the last quarter. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Halozyme Therapeutics during the 2nd quarter valued at about $1,025,000. Great Lakes Advisors LLC acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $2,821,000. Finally, Chase Investment Counsel Corp acquired a new position in shares of Halozyme Therapeutics in the 2nd quarter valued at about $2,035,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

Halozyme Therapeutics Price Performance

HALO stock opened at $103.63 on Monday. The firm has a market cap of $11.81 billion, a PE ratio of 26.37, a P/E/G ratio of 0.39 and a beta of 0.92. The company has a debt-to-equity ratio of 13.50, a quick ratio of 3.60 and a current ratio of 3.88. The firm’s fifty day moving average is $115.19 and its 200 day moving average is $84.73. Halozyme Therapeutics, Inc. has a one year low of $61.22 and a one year high of $134.00.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings data on Thursday, November 5th. The biopharmaceutical company reported $2.39 earnings per share for the quarter, topping analysts’ consensus estimates of $2.30 by $0.09. Halozyme Therapeutics had a net margin of 26.93% and a return on equity of 751.81%. The business had revenue of $492.97 million during the quarter, compared to the consensus estimate of $491.63 million. During the same quarter in the prior year, the firm posted $1.72 earnings per share. The company’s revenue was up 39.1% compared to the same quarter last year. On average, research analysts forecast that Halozyme Therapeutics, Inc. will post 8.32 EPS for the current year.

Wall Street Analyst Weigh In

A number of analysts have recently commented on HALO shares. Wells Fargo & Company upped their target price on Halozyme Therapeutics from $95.00 to $110.00 and gave the stock an “equal weight” rating in a research note on Friday. TD Cowen raised their target price on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research report on Monday, August 31st. Zacks Research raised Halozyme Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 13th. Finally, Leerink Partners upgraded Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and upped their price objective for the stock from $83.00 to $110.00 in a research report on Friday, August 7th. One equities research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $106.09.

Halozyme Therapeutics News Summary

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Q3 revenue rose 39% year over year to $493 million and adjusted EPS of $2.39 beat estimates. Record royalty revenue increased 44% to $341 million. Halozyme also raised its 2026 revenue, royalty, EBITDA and adjusted EPS guidance. Q3 results and guidance
• Positive Sentiment: The FDA approved Johnson & Johnson’s RYBREVANT FASPRO, which uses Halozyme’s ENHANZE technology, for certain patients with advanced head and neck cancer. The expanded use could support future royalties. FDA approval
• Positive Sentiment: Halozyme said its analysis of Medicare’s drug-price negotiation rule indicates zero to minimal impact on royalty revenue through at least 2035, easing a potential long-term concern. Medicare rule assessment
• Neutral Sentiment: Citizens JMP raised its price target to $149 and maintained an outperform rating, while Wells Fargo raised its target to $110 but kept an equal-weight rating—signaling differing views on further upside. Citizens JMP rating
• Negative Sentiment: Despite the earnings beat and higher guidance, reports noted a negative share reaction and questions around the guidance reset, suggesting results may not have met elevated investor expectations. The Merck patent dispute also remains an investor focus. Earnings reaction and guidance questions

Insider Activity

In related news, Director Matthew Posard sold 18,996 shares of Halozyme Therapeutics stock in a transaction dated Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the completion of the transaction, the director owned 58,839 shares in the company, valued at $6,339,313.86. The trade was a 24.41% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the company’s stock in a transaction dated Wednesday, September 9th. The stock was sold at an average price of $107.43, for a total value of $2,148,600.00. Following the completion of the transaction, the chief executive officer directly owned 767,780 shares of the company’s stock, valued at $82,482,605.40. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 124,226 shares of company stock valued at $13,370,893. 2.50% of the stock is owned by company insiders.

Halozyme Therapeutics Profile

Halozyme Therapeutics, Inc is a biotechnology company focused on developing drug-delivery technologies and medicines. Its ENHANZE platform uses a recombinant human hyaluronidase enzyme, rHuPH20, to temporarily modify tissue under the skin and help enable the subcutaneous administration of certain biologic medicines that might otherwise require intravenous infusion.

Halozyme licenses ENHANZE to pharmaceutical and biotechnology partners, which use the technology in their own products. The company also markets Hylenex recombinant, a hyaluronidase product used to facilitate the dispersion and absorption of other injected medicines and fluids.

Founded in 1998 and based in San Diego, California, Halozyme serves patients in multiple countries through its own commercial activities and, particularly for ENHANZE-enabled medicines, through its licensing partners.